Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma.
BACKGROUND
Sunitinib is approved for treatment of advanced renal cell carcinoma (RCC). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation.


METHODS
In a retrospective review of RCC patients treated at a single centre, data on treatment duration, hematology parameters, concomitant medications, vitamin B₁₂and folate levels, and thyroid function were recorded.


RESULTS
The 43 patients reviewed had received a median of 5 cycles of sunitinib. Overall, 21 patients (49%) developed macrocytosis after a median of 3 cycles. Of the 9 patients that received 2 or fewer cycles, none developed macrocytosis. Among patients with macrocytosis, 9 (43%) had anemia at the time macrocytosis was first documented. In patients who did not develop macrocytosis, 82% showed a trend of increasing mean corpuscular volume.


CONCLUSIONS
Treatment with sunitinib in patients with RCC can cause macrocytosis. The frequency of macrocytosis increases with duration of treatment. The mechanism of sunitinib-associated macrocytosis remains to be elucidated.
Price
J
J
Department of Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB.
Shaarbaf
R
R
Wood
L
L
Am J Clin Oncol. 2004 Aug;27(4):364-8
15289729
Anticancer Drugs. 2003 Feb;14(2):119-23
12569298
N Engl J Med. 2007 Sep 27;357(13):1351-2; author reply 1352
17898111
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Clin Med Res. 2006 Sep;4(3):236-41
16988104
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
17202116
N Engl J Med. 2007 May 31;356(22):2330-1
17538098
Ann Intern Med. 2006 Nov 7;145(9):660-4
17088579
Cancer. 2008 Sep 15;113(6):1309-14
18618496